These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 27471394)

  • 1. Decreased expression of SLC 39A14 is associated with tumor aggressiveness and biochemical recurrence of human prostate cancer.
    Xu XM; Wang CG; Zhu YD; Chen WH; Shao SL; Jiang FN; Liao QD
    Onco Targets Ther; 2016; 9():4197-205. PubMed ID: 27471394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of Rab25 contributes to malignant phenotypes and biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Hu C; Chen B; Zhou Y; Shan Y
    Cancer Cell Int; 2017; 17():45. PubMed ID: 28400705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
    Chen C; Cai Z; Zhuo Y; Xi M; Lin Z; Jiang F; Liu Z; Wan Y; Zheng Y; Li J; Zhou X; Zhu J; Zhong W
    BMC Cancer; 2020 Apr; 20(1):289. PubMed ID: 32252682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
    Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
    Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased expression of TCF12 contributes to progression and predicts biochemical recurrence in patients with prostate cancer.
    Chen QB; Liang YK; Zhang YQ; Jiang MY; Han ZD; Liang YX; Wan YP; Yin J; He HC; Zhong WD
    Tumour Biol; 2017 Jun; 39(6):1010428317703924. PubMed ID: 28651494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
    Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
    Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of PDZ-binding kinase confers malignant phenotype in prostate cancer via the regulation of E2F1.
    Chen JH; Liang YX; He HC; Chen JY; Lu JM; Chen G; Lin ZY; Fu X; Ling XH; Han ZD; Jiang FN; Zhong WD
    Int J Biol Macromol; 2015 Nov; 81():615-23. PubMed ID: 26314905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of BUB1B contributes to progression of prostate cancer and predicts poor outcome in patients with prostate cancer.
    Fu X; Chen G; Cai ZD; Wang C; Liu ZZ; Lin ZY; Wu YD; Liang YX; Han ZD; Liu JC; Zhong WD
    Onco Targets Ther; 2016; 9():2211-20. PubMed ID: 27143916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer.
    Jiang D; Xiao C; Xian T; Wang L; Mao Y; Zhang J; Pang J
    Onco Targets Ther; 2018; 11():1077-1086. PubMed ID: 29535532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer.
    Huang YQ; Han ZD; Liang YX; Lin ZY; Ling XH; Fu X; Cai C; Bi XC; Dai QS; Chen JH; He HC; Chen YR; Jiang FN; Zhong WD
    Med Oncol; 2014 Jan; 31(1):820. PubMed ID: 24338276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
    Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
    Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of SRPK2 contributes to aggressive progression and metastasis in prostate cancer.
    Zhuo YJ; Liu ZZ; Wan S; Cai ZD; Xie JJ; Cai ZD; Song SD; Wan YP; Hua W; Zhong W; Wu CL
    Biomed Pharmacother; 2018 Jun; 102():531-538. PubMed ID: 29587239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein regulator of cytokinesis 1 overexpression predicts biochemical recurrence in men with prostate cancer.
    Luo HW; Chen QB; Wan YP; Chen GX; Zhuo YJ; Cai ZD; Luo Z; Han ZD; Liang YX; Zhong WD
    Biomed Pharmacother; 2016 Mar; 78():116-120. PubMed ID: 26898432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
    Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
    Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.
    Zheng QS; Chen SH; Wu YP; Chen HJ; Chen H; Wei Y; Li XD; Huang JB; Xue XY; Xu N
    J Cancer; 2018; 9(6):959-967. PubMed ID: 29581775
    [No Abstract]   [Full Text] [Related]  

  • 19. SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer.
    Yuan D; Wang W; Su J; Zhang Y; Luan B; Rao H; Cheng T; Zhang W; Xiao S; Zhang M; Jiang FN; Sun Z; Jia Z; Zhong WD; Zhu J
    Curr Cancer Drug Targets; 2018; 18(9):894-904. PubMed ID: 29295692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
    Zhang L; Guo F; Gao X; Wu Y
    Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.